JIPOAd
JIPOAd
PARP
ESID
  • Users Online: 101
  • Print this page
  • Email this page

    Article Cited by others

EDITORIAL

Being realistic and optimistic in curing cancer

Naing Aung

Year : 2018| Volume: 1| Issue : 2 | Page no: 53-55

   This article has been cited by
 
1 A new screening tool for FGFR inhibitor treatment?
Aung Naing
The Lancet Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
2 Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
Dylan J. Martini,Yuan Liu,Julie M. Shabto,Colleen Lewis,Meredith R. Kline,Hannah Collins,Mehmet Akce,Haydn T. Kissick,Bradley C. Carthon,Walid L. Shaib,Olatunji B. Alese,Rathi N. Pillai,Conor E. Steuer,Christina S. Wu,David H. Lawson,Ragini R. Kudchadkar,Viraj A. Master,Bassel F. El-Rayes,Suresh S. Ramalingam,Taofeek K. Owonikoko,R. Donald Harvey,Mehmet Asim Bilen
Investigational New Drugs. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Lihu Gu,Parikshit Asutosh Khadaroo,Hui Su,Liya Kong,Liangliang Chen,Xianfa Wang,Xinlong Li,Hepan Zhu,Xin Zhong,Junhai Pan,Manman Chen
BMC Cancer. 2019; 19(1)
[Pubmed]  [Google Scholar] [DOI]
4 Optimizing Precision Oncology and Immunotherapy Strategies: Moving into the Next Stage of Cancer Medicine
Phoebe Lewis,TimothyA Yap
Journal of Immunotherapy and Precision Oncology. 2019; 2(1): 1
[Pubmed]  [Google Scholar] [DOI]
5 Opening new boundaries in biomarker detection: Awakening of middle east and North Africa Region
Christian Rolfo,Umberto Malapelle
Journal of Immunotherapy and Precision Oncology. 2019; 2(1): 8
[Pubmed]  [Google Scholar] [DOI]
6 Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing,Deborah J Wong,Jeffrey R Infante,W Michael Korn,Raid Aljumaily,Kyriakos P Papadopoulos,Karen A Autio,Shubham Pant,Todd M Bauer,Alexandra Drakaki,Naval G Daver,Annie Hung,Navneet Ratti,Scott McCauley,Peter Van Vlasselaer,Rakesh Verma,David Ferry,Martin Oft,Adi Diab,Edward B Garon,Nizar M Tannir
The Lancet Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
7 Tackling immunotherapy resistance: Developing rational combinations of immunotherapy and targeted drugs
Elena Cojocaru,Mariana Scaranti,Anna Minchom
Journal of Immunotherapy and Precision Oncology. 2019; 2(2): 23
[Pubmed]  [Google Scholar] [DOI]

 

Read this article